nach oben

Die Pathologie

Erschienen in:

05.05.2021 | Biomarker | Schwerpunkt: Prädiktive molekulare Pathologie für die gezielte Tumortherapie

Prädiktive Diagnostik für Checkpoint-Inhibitoren

verfasst von: Hans-Ulrich Schildhaus, Wilko Weichert

Erschienen in: Die Pathologie | Ausgabe 4/2021

Einloggen, um Zugang zu erhalten

Zusammenfassung

Checkpointinhibitoren haben in vielen Entitäten die onkologische Behandlung revolutioniert und dem etablierten medikamentösen Arsenal in der Onkologie eine neue, sehr mächtige immunonkologische Behandlungsmodalität zur Seite gestellt. In Mono- und auch in Kombinationstherapien sprechen jedoch selbst in grundsätzlich responsiven Entitäten nicht alle Patienten gleichermaßen gut an. Daher liegt seit Einführung dieser Therapien ein wesentlicher Fokus auch auf der Erforschung und Implementierung prädiktiver Marker zur Patientenselektion. Der erste zulassungsrelevante Biomarker, die Expression des Zielmoleküls PD-L1, hat inzwischen in einer Vielzahl leider sehr divergenter diagnostischer Konstellationen in multiplen Entitäten Einzug in die Routinediagnostik gehalten. Ebenfalls erforscht und teilweise auch bereits in unterschiedlichem Maße implementiert wurden darüber hinaus einige molekulare Prädiktoren, inklusive der Messung von Mikrosatelliteninstabilität und Tumormutationslast. Einige weitere Parameter wurden vorgeschlagen, haben jedoch noch nicht den Weg in die Routineanwendung gefunden. In diesem Übersichtsartikel werden der aktuelle Stand und neue Entwicklungen zur Prädiktion im Kontext einer Immuncheckpointblockade diskutiert.

Schildhaus HU (2018) Predictive value of PD-L1 diagnostics. Pathologe 39:498–519PubMed

Weichert W (2018) Molecular predictors in immune oncology. Pathologe 39:546–555PubMed

Yarchoan M, Albacker LA, Hopkins AC et al (2019) PD-L1 expression and tumor mutational burden are independent biomarkers in most cancers. JCI Insight 4(6):e126908. https://doi.org/10.1172/jci.insight.126908CrossRefPubMedCentral

Shen X, Zhao B (2018) Efficacy of PD‑1 or PD-L1 inhibitors and PD-L1 expression status in cancer: meta-analysis. BMJ 362:k3529PubMedPubMedCentral

Reck M, Rodriguez-Abreu D, Robinson AG et al (2019) Updated analysis of keynote-024: pembrolizumab versus platinum-based chemotherapy for advanced non-small-cell lung cancer with PD-L1 tumor proportion score of 50 % or greater. J Clin Oncol 37:537–546PubMed

Antonia SJ, Villegas A, Daniel D et al (2018) Overall survival with durvalumab after chemoradiotherapy in stage III NSCLC. N Engl J Med 379:2342–2350PubMed

Hirsch FR, McElhinny A, Stanforth D et al (2017) PD-L1 immunohistochemistry assays for lung cancer: results from phase 1 of the blueprint PD-L1 IHC assay comparison project. J Thorac Oncol 12:208–222PubMed

Scheel AH, Baenfer G, Baretton G et al (2018) Interlaboratory concordance of PD-L1 immunohistochemistry for non-small-cell lung cancer. Histopathology 72:449–459PubMed

Scheel AH, Dietel M, Heukamp LC et al (2016) Harmonized PD-L1 immunohistochemistry for pulmonary squamous-cell and adenocarcinomas. Mod Pathol 29:1165–1172PubMed

10.

Tsao MS, Kerr KM, Kockx M et al (2018) PD-L1 immunohistochemistry comparability study in real-life clinical samples: results of blueprint phase 2 project. J Thorac Oncol 13:1302–1311PubMedPubMedCentral

11.

Herbst RS, Giaccone G, de Marinis F et al (2020) Atezolizumab for first-line treatment of PD-L1-selected patients with NSCLC. N Engl J Med 383:1328–1339PubMed

12.

Schmid P, Adams S, Rugo HS et al (2018) Atezolizumab and nab-paclitaxel in advanced triple-negative breast cancer. N Engl J Med 379:2108–2121PubMed

13.

Cortes J, Cescon DW, Rugo HS et al (2020) Pembrolizumab plus chemotherapy versus placebo plus chemotherapy for previously untreated locally recurrent inoperable or metastatic triple-negative breast cancer (Keynote-355): a randomised, placebo-controlled, double-blind, phase 3 clinical trial. Lancet 396:1817–1828PubMed

14.

Noske A, Ammann JU, Wagner DC et al (2020) A multicentre analytical comparison study of inter-reader and inter-assay agreement of four programmed death-ligand 1 immunohistochemistry assays for scoring in triple-negative breast cancer. Histopathology 78(4):567–577. https://doi.org/10.1111/his.14254CrossRefPubMed

15.

Rugo H, Loi S, Adams S et al (2020) Abstract PD1-07: exploratory analytical harmonization of PD-L1 immunohistochemistry assays in advanced triple-negative breast cancer: a retrospective substudy of IMpassion130. Cancer Res. https://doi.org/10.1158/1538-7445.SABCS19-PD1-07CrossRef

16.

Rugo HS, Loi S, Adams S et al (2019) LBA20—performance of PD-L1 immunohistochemistry (IHC) assays in unresectable locally advanced or metastatic triple-negative breast cancer (mTNBC): post-hoc analysis of IMpassion130. Ann Oncol 30:v858–v859

17.

Scott M, Scorer P, Barker C et al (2019) 10O—comparison of patient populations identified by different PD-L1 assays in in triple-negative breast cancer (TNBC). Ann Oncol 30:iii4

18.

Downes MR, Slodkowska E, Katabi N et al (2020) Inter- and intraobserver agreement of programmed death ligand 1 scoring in head and neck squamous cell carcinoma, urothelial carcinoma and breast carcinoma. Histopathology 76:191–200PubMed

19.

Balar AV, Castellano D, O’Donnell PH et al (2017) First-line pembrolizumab in cisplatin-ineligible patients with locally advanced and unresectable or metastatic urothelial cancer (keynote-052): a multicentre, single-arm, phase 2 study. Lancet Oncol 18:1483–1492PubMed

20.

Balar AV, Galsky MD, Rosenberg JE et al (2017) Atezolizumab as first-line treatment in cisplatin-ineligible patients with locally advanced and metastatic urothelial carcinoma: a single-arm, multicentre, phase 2 trial. Lancet 389:67–76PubMed

21.

Eckstein M, Erben P, Kriegmair MC et al (2019) Performance of the food and drug administration/EMA-approved programmed cell death ligand‑1 assays in urothelial carcinoma with emphasis on therapy stratification for first-line use of atezolizumab and pembrolizumab. Eur J Cancer 106:234–243PubMed

22.

Eckstein M, Wirtz RM, Pfannstil C et al (2018) A multicenter round robin test of PD-L1 expression assessment in urothelial bladder cancer by immunohistochemistry and RT-qPCR with emphasis on prognosis prediction after radical cystectomy. Oncotarget 9:15001–15014PubMedPubMedCentral

23.

Hodgson A, Slodkowska E, Jungbluth A et al (2018) PD-L1 immunohistochemistry assay concordance in urothelial carcinoma of the bladder and hypopharyngeal squamous cell carcinoma. Am J Surg Pathol 42:1059–1066PubMedPubMedCentral

24.

Schwamborn K, Ammann JU, Knuchel R et al (2019) Multicentric analytical comparability study of programmed death-ligand 1 expression on tumor-infiltrating immune cells and tumor cells in urothelial bladder cancer using four clinically developed immunohistochemistry assays. Virchows Arch 475:599–608PubMedPubMedCentral

25.

Powles T, Park SH, Voog E et al (2020) Avelumab maintenance therapy for advanced or metastatic urothelial carcinoma. N Engl J Med 383:1218–1230PubMed

26.

Burtness B, Harrington KJ, Greil R et al (2019) Pembrolizumab alone or with chemotherapy versus cetuximab with chemotherapy for recurrent or metastatic squamous cell carcinoma of the head and neck (keynote-048): a randomised, open-label, phase 3 study. Lancet 394:1915–1928PubMed

27.

Cohen EEW, Soulieres D, Le Tourneau C et al (2019) Pembrolizumab versus methotrexate, docetaxel, or cetuximab for recurrent or metastatic head-and-neck squamous cell carcinoma (keynote-040): a randomised, open-label, phase 3 study. Lancet 393:156–167PubMed

28.

de Ruiter EJ, Mulder FJ, Koomen BM et al (2020) Comparison of three PD-L1 immunohistochemical assays in head and neck squamous cell carcinoma (HNSCC). Mod Pathol. https://doi.org/10.1038/s41379-020-0644-7CrossRefPubMed

29.

Kojima T, Shah MA, Muro K et al (2020) Randomized phase III keynote-181 study of pembrolizumab versus chemotherapy in advanced esophageal cancer. J Clin Oncol 38:4138–4148PubMed

30.

Kato K, Sun JM, Shah MA et al (2020) LBA8_PR pembrolizumab plus chemotherapy versus chemotherapy as first-line therapy in patients with advanced esophageal cancer: the phase 3 keynote-590 study. Ann Oncol 31:S1192–S1193

31.

Moehler M, Shitara K, Garrido M et al (2020) LBA6_PR nivolumab (nivo) plus chemotherapy (chemo) versus chemo as first-line (1L) treatment for advanced gastric cancer/gastroesophageal junction cancer (GC/GEJC)/esophageal adenocarcinoma (EAC): first results of the checkmate 649 study. Ann Oncol 31:S1191

32.

Shitara K, Van Cutsem E, Bang YJ et al (2020) Efficacy and safety of pembrolizumab or pembrolizumab plus chemotherapy vs chemotherapy alone for patients with first-line, advanced gastric cancer: the keynote-062 phase 3 randomized clinical trial. JAMA Oncol 6:1571–1580PubMed

33.

Park Y, Koh J, Na HY et al (2020) PD-L1 testing in gastric cancer by the combined positive score of the 22C3 pharmdx and SP263 assay with clinically relevant cut-offs. Cancer Res Treat 52:661–670PubMedPubMedCentral

34.

Schmid P, Hegde PS, Zou W et al (2016) Association of PD-L2 expression in human tumors with atezolizumab activity. J Clin Oncol 34:11506–11506

35.

Braun DA, Burke KP, Van Allen EM (2016) Genomic approaches to understanding response and resistance to immunotherapy. Clin Cancer Res 22:5642–5650PubMedPubMedCentral

36.

Anagnostou V, Bruhm DC, Niknafs N et al (2020) Integrative tumor and immune cell multi-omic analyses predict response to immune checkpoint blockade in melanoma. Cell Rep Med 1:100139PubMedPubMedCentral

37.

Keenan TE, Burke KP, Van Allen EM (2019) Genomic correlates of response to immune checkpoint blockade. Nat Med 25:389–402PubMedPubMedCentral

38.

Kim ST, Cristescu R, Bass AJ et al (2018) Comprehensive molecular characterization of clinical responses to PD‑1 inhibition in metastatic gastric cancer. Nat Med 24:1449–1458PubMed

39.

Panda A, Mehnert JM, Hirshfield KM et al (2018) Immune activation and benefit from avelumab in EBV-positive gastric cancer. J Natl Cancer Inst 110:316–320PubMed

40.

Gopalakrishnan V, Spencer CN, Nezi L et al (2018) Gut microbiome modulates response to anti-PD‑1 immunotherapy in melanoma patients. Science 359:97–103PubMed

41.

Routy B, Le Chatelier E, Derosa L et al (2018) Gut microbiome influences efficacy of PD-1-based immunotherapy against epithelial tumors. Science 359:91–97PubMed

42.

Overman MJ, Lonardi S, Wong KYM et al (2018) Durable clinical benefit with nivolumab plus ipilimumab in DNA mismatch repair-deficient/microsatellite instability-high metastatic colorectal cancer. J Clin Oncol 36:773–779PubMed

43.

Lenz H‑J, Lonardi S, Zagonel V et al (2020) Nivolumab plus low-dose ipilimumab as first-line therapy in microsatellite instability-high/DNA mismatch repair deficient metastatic colorectal cancer: clinical update. J Clin Oncol 38:11–11

44.

Andre T, Shiu KK, Kim TW et al (2020) Pembrolizumab in microsatellite-instability-high advanced colorectal cancer. N Engl J Med 383:2207–2218PubMed

45.

Marabelle A, Le DT, Ascierto PA et al (2020) Efficacy of pembrolizumab in patients with noncolorectal high microsatellite instability/mismatch repair-deficient cancer: results from the phase II keynote-158 study. J Clin Oncol 38:1–10PubMed

46.

Dietmaier W, Buttner R, Ruschoff J (2019) Microsatellite instability : review of methods and applications. Pathologe 40:313–327PubMed

47.

Hellmann MD, Ciuleanu TE, Pluzanski A et al (2018) Nivolumab plus ipilimumab in lung cancer with a high tumor mutational burden. N Engl J Med 378:2093–2104PubMedPubMedCentral

48.

Marabelle A, Fakih M, Lopez J et al (2020) Association of tumour mutational burden with outcomes in patients with advanced solid tumours treated with pembrolizumab: prospective biomarker analysis of the multicohort, open-label, phase 2 keynote-158 study. Lancet Oncol 21:1353–1365PubMed

49.

Samstein RM, Lee CH, Shoushtari AN et al (2019) Tumor mutational load predicts survival after immunotherapy across multiple cancer types. Nat Genet 51:202–206PubMedPubMedCentral

50.

Budczies J, Kazdal D, Allgauer M et al (2020) Quantifying potential confounders of panel-based tumor mutational burden (TMB) measurement. Cancer Treat Res 142:114–119

51.

Endris V, Buchhalter I, Allgauer M et al (2019) Measurement of tumor mutational burden (TMB) in routine molecular diagnostics: in silico and real-life analysis of three larger gene panels. Int J Cancer 144:2303–2312PubMed

52.

Stenzinger A, Endris V, Budczies J et al (2020) Harmonization and standardization of panel-based tumor mutational burden measurement: real-world results and recommendations of the quality in pathology study. J Thorac Oncol 15:1177–1189PubMed

53.

Peters S, Cho BC, Reinmuth N et al (2019) Abstract CT074: tumor mutational burden (TMB) as a biomarker of survival in metastatic non-small cell lung cancer (mNSCLC): blood and tissue TMB analysis from mystic, a phase III study of first-line durvalumab ± tremelimumab vs chemotherapy. Cancer Res 79:CT074-CT074

54.

Socinski M, Velcheti V, Mekhail T et al (2019) LBA83—final efficacy results from B‑F1RST, a prospective phase II trial evaluating blood-based tumour mutational burden (bTMB) as a predictive biomarker for atezolizumab (atezo) in 1L non-small cell lung cancer (NSCLC). Ann Oncol 30:v919–v920

55.

Wang F, Zhao Q, Wang YN et al (2019) Evaluation of POLE and POLD1 mutations as biomarkers for immunotherapy outcomes across multiple cancer types. JAMA Oncol 5(10):1504–1506. https://doi.org/10.1001/jamaoncol.2019.2963CrossRefPubMedPubMedCentral

56.

Shire NJ, Klein AB, Golozar A et al (2020) STK11 (LKB1) mutations in metastatic NSCLC: prognostic value in the real world. PLoS ONE 15:e238358PubMedPubMedCentral

57.

Skoulidis F, Goldberg ME, Greenawalt DM et al (2018) STK11/LKB1 mutations and PD‑1 inhibitor resistance in KRAS-mutant lung adenocarcinoma. Cancer Discov 8:822–835PubMedPubMedCentral

58.

Rizvi N, Cho BC, Reinmuth N et al (2019) OA04.07 mutations associated with sensitivity or resistance to immunotherapy in mNSCLC: analysis from the mystic trial. J Thorac Oncol 14:S217

59.

Ayers M, Lunceford J, Nebozhyn M et al (2017) IFN-gamma-related mRNA profile predicts clinical response to PD‑1 blockade. J Clin Invest 127:2930–2940PubMedPubMedCentral

60.

Cristescu R, Mogg R, Ayers M et al (2018) Pan-tumor genomic biomarkers for PD‑1 checkpoint blockade-based immunotherapy. Science 362(6411):eaar3593. https://doi.org/10.1126/science.aar3593CrossRefPubMedPubMedCentral

61.

Stenzinger A, Weichert W (2020) Impact of the novel in vitro diagnostic regulation (IVDR) of the European Union on pathology laboratories. What’s important? Pathologe 41:129–133PubMed

Titel: Prädiktive Diagnostik für Checkpoint-Inhibitoren
verfasst von: Hans-Ulrich Schildhaus
Wilko Weichert
Publikationsdatum: 05.05.2021
Verlag: Springer Medizin
Schlagwörter: Biomarker
Checkpoint-Inhibitoren
Checkpoint-Inhibitoren
Erschienen in: Die Pathologie / Ausgabe 4/2021
Print ISSN: 2731-7188
Elektronische ISSN: 2731-7196
DOI: https://doi.org/10.1007/s00292-021-00939-4

Passend zum Thema

Neue ESMO-Clinical Practice Guidelines 2023 zum fortgeschrittenen mNSCLC

Mit dem Update der Clinical Practice Guidelines 2023 zum metastasierenden nicht-kleinzelligen Lungenkarzinom (mNSCLC) trägt die ESMO der in den letzten Jahren immer weiter gewachsenen Anzahl an Therapieoptionen Rechnung.

NOVUM Onkologie – Fortbildungsreihe zum NSCLC

Mit NOVUM Onkologie veranstaltet MSD regelmäßig Online-Fortbildungen zum Thema Lungenkarzinom. Bei dem mittlerweile etablierten Format erhalten Teilnehmende die Möglichkeit sich bei Expertendiskussionen zu praxisrelevanten Themen der pneumologischen Onkologie weiterzubilden.

Fokus Immunonkologie – NSCLC

Content Hub

Die Einführung von Immun-Checkpoint-Inhibitoren markierte einen entscheidenden Fortschritt in der Behandlung von bestimmten Patienten mit nicht-kleinzelligem Lungenkarzinom (non-small cell lung cancer, NSCLC) und eröffnete seither neue Perspektiven und Chancen für Behandler und geeignete Patienten. Hier finden Sie fortlaufend aktuelle Informationen und relevante Beiträge zur Immunonkologie in dieser Indikation.

Springer Medizin

Zusammenfassung

Bitte loggen Sie sich ein, um Zugang zu diesem Inhalt zu erhalten

Weitere Artikel der Ausgabe 4/2021

Wilhelm His Senior und die Entwicklung der Paraffineinbettung

Next Generation Sequencing in der Pathologie

Mitteilungen der Österreichischen Gesellschaft für Klinische Pathologie und Molekularpathologie

Mitteilungen des Bundesverbandes Deutscher Pathologen

Onkologische Diagnostik: DNA-Reparaturdefekte als prädiktive Marker

Varianteninterpretation in der molekularen Pathologie und Onkologie

Passend zum Thema

Neue ESMO-Clinical Practice Guidelines 2023 zum fortgeschrittenen mNSCLC

NOVUM Onkologie – Fortbildungsreihe zum NSCLC

Fokus Immunonkologie – NSCLC